Citations

Clear

3042 citation(s) found for "Kumar, S".

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Podar, Klaus , Tonon, Giovanni , Sattler, Martin , Gouill, Steven Le , Yasui, Hiroshi , Ishitsuka, Kenji , Kumar, Shaji , Pandite, Lini , Hideshima, Teru , Chauhan, Dharminder , Tai, Yu‐Tzu , Kumar, Rakesh , Anderson, Kenneth C.

Mayo Clinic

Proceedings of the National Academy of Sciences | December 12, 2006 | Volume: 103 | Issue: 51 | Pages: 19478-19483

10.1073/pnas.0609329103 | PMID 17164332 Get It

A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenesis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Yazan, Ngo, Hai T., Runnels, Judith, Leleu, Xavier , Singha, Ujjal K. , Pitsillides, Costas, Spencer, Joel A. , Kimlinger, Teresa K. , Jia, Xiaoying , Lu, Ganwei, Timm, Michael, Côté, Daniel , Veilleux, Israël , Hedin, Karen E. , Roodman, G. David, Kung, Andrew L. , Hideshima, Teru , Lin, Charles P. , Ghobrial, Joanna M. , Kumar, Ashok , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M.

Mayo Clinic

Blood | November 22, 2006 | Volume: 109 | Issue: 7 | Pages: 2708-2717

10.1182/blood-2006-07-035857 | PMID 17119115 Get It

Abstract The mechanisms by which multiple myeloma (MM) cells migrate and home to the bone marrow are not well understood. In this study, we sought to determine the effect of the chemokine SDF-1 (CXCL12) and its receptor CXCR4 on the migration and homing of MM cells. We demonstrated that CXCR4 is differentially expressed at high levels in the peripheral blood and is down-regulated in the bone marrow in response to high levels of SDF-1. SDF-1 induced motility, internalization, and cytoskeletal rearrangement in MM cells evidenced by confocal microscopy. The specific CXCR4 inhibitor AMD3100 and the anti-CXCR4 antibody MAB171 inhibited the migration of MM cells in vitro. CXCR4 knockdown experiments demonstrated that SDF-1–dependent migration was regulated by the PI3K and ERK/MAPK pathways but not by p38 MAPK. In addition, we demonstrated that AMD3100 inhibited the homing of MM cells to the bone marrow niches using in vivo flow cytometry, in vivo confocal microscopy, and whole body bioluminescence imaging. This study, therefore, demonstrates that SDF-1/CXCR4 is a critical regulator of MM homing and that it provides the framework for inhibitors of this pathway to be used in future clinical trials to abrogate MM trafficking.
Application of Liquid Chromatography–Mass Spectrometry Technology for Early Detection of Microalbuminuria in Patients with Kidney Disease
Babić, Nikolina , Larson, TS, Grebe, S K, Turner, ST, Kumar, Rajiv , Singh, RJ, Turner, ST, Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | October 26, 2006 | Volume: 52 | Issue: 11 | Pages: 2155-2157

10.1373/clinchem.2006.072892 | PMID 18050524 Get It

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Dispenzieri, Angela , Lacy, Martha Q. , Zeldenrust, Steven R., Hayman, Suzanne R. , Kumar, Shaji , Geyer, Susan M. , Lust, John A., Allred, Jacob B., Rajkumar, S. Vincent , Greipp, Philip R., Kabat, Brian, Witzig, Thomas E. , Russell, Stephen J. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | September 29, 2006 | Volume: 109 | Issue: 2 | Pages: 465-470

10.1182/blood-2006-07-032987 | PMID 17008538 Get It

AbstractPrimary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.
Phosphatonins and the Regulation of Phosphate Homeostasis
Berndt, Theresa J., Kumar, Rajiv

Mayo Clinic

Annual Review of Physiology | September 5, 2006 | Volume: 69 | Issue: 1 | Pages: 341-359

10.1146/annurev.physiol.69.040705.141729 | PMID 17002592 Get It

Inorganic phosphate (Pi) is required for energy metabolism, nucleic acid synthesis, bone mineralization, and cell signaling. The activity of cell-surface sodium-phosphate (Na+-Pi) cotransporters mediates the uptake of Pi from the extracellular environment. Na+-Pi cotransporters and organ-specific Pi absorptive processes are regulated by peptide and sterol hormones, such as parathyroid hormone (PTH) and 1α,25-dihydroxyvitamin D (1α,25(OH)2D3), which interact in a coordinated fashion to regulate Pi homeostasis. Recently, several phosphaturic peptides such as fibroblast growth factor-23 (FGF-23), secreted frizzled related protein-4 (sFRP-4), matrix extracellular phosphoglycoprotein, and fibroblast growth factor-7 have been demonstrated to play a pathogenic role in several hypophosphatemic disorders. By inhibiting Na+-Pi transporters in renal epithelial cells, these proteins increase renal Pi excretion, resulting in hypophosphatemia. FGF-23 and sFRP-4 inhibit 25-hydroxyvitamin D 1α-hydroxylase activity, reducing 1α,25(OH)2D3 synthesis and thus intestinal Pi absorption. This review examines the role of these factors in Pi homeostasis in health and disease.
Role of dynamic CT myelography in identifying the etiology of superficial siderosis
Kumar, Neeraj , Lindell, E. Paul , Wilden, Jessica A., Davis, D.H.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 65 | Issue: 3 | Pages: 486-488

10.1212/01.wnl.0000172345.05810.14 | PMID 16087925 Get It

Neurologic manifestations in welders with pallidal MRI T1 hyperintensity
Josephs, Keith A. , Ahlskog, J. Eric , Klos, Kevin J., Kumar, Neeraj , Fealey, Robert D., Trenerry, Max R., Cowl, Clayton T.

Mayo Clinic

Neurology | July 12, 2006 | Volume: 64 | Issue: 12 | Pages: 2033-2039

10.1212/01.wnl.0000167411.93483.a1 | PMID 15888601 Get It

Metal-binding properties of human centrin-2 determined by micro-electrospray ionization mass spectrometry and UV spectroscopy
Craig, Theodore A., Benson, Linda M., Bergen, H. Robert, Venyaminov, S.Yu., Salisbury, Jeffrey L., Ryan, Zachary C. , Thompson, James R. , Sperry, Justin B. , Gross, Michael L. , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of the American Society for Mass Spectrometry | June 7, 2006 | Volume: 17 | Issue: 8 | Pages: 1158-1171

10.1016/j.jasms.2006.04.029 | PMID 16750384 Get It

Mutation in the ATP7A gene may not be responsible for hypocupraemia in copper deficiency myelopathy
Kumar, Neeraj , Gross, John B.

Mayo Clinic

Postgraduate Medical Journal | June 5, 2006 | Volume: 82 | Issue: 968 | Pages: 416-416

10.1136/pgmj.2005.043505 | PMID 16754714 Get It

Vitamin D–Resistant Rickets and Type 1 Diabetes in a Child With Compound Heterozygous Mutations of the Vitamin D Receptor (L263R and R391S): Dissociated Responses of the CYP-24 and rel-B Promoters to 1,25-Dihydroxyvitamin D3
d’Alésio, Arnold, Pascussi, Jean‐Marc , Kumar, Rajiv , Griffin, Matthew D. , Dong, Xiangyang , Guillozo, H., Rizk‐Rabin, Marthe , Sinding, Christiane, Bougnères, Pierre , Jehan, Frédéric, Garabédian, Michèle, Nguyen, Tuan M. , Griffin, Matthew D , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | June 5, 2006 | Volume: 21 | Issue: 6 | Pages: 886-894

10.1359/jbmr.060307 | PMID 16753019 Get It

Abstract We report here the first association between vitamin D–resistant rickets, alopecia, and type 1 diabetes in a child with compound heterozygous mutations in the VDR gene. Transfection studies suggest dissociated effects of VDR gene mutations on the regulation of genes involved in vitamin D metabolism and dendritic cell maturation. Introduction: Whereas vitamin D may play a role in the immune tolerance process, no patient has been reported to associate hereditary vitamin D–resistant rickets (HVDRR) and an autoimmune disease, and no attempt has been made to delineate the outcome of mutations of the vitamin D receptor (VDR) on the transcription of genes controlling immune tolerance. Materials and Methods: The VDR gene was analyzed in a child with vitamin D–resistant rickets, total alopecia, and early childhood–onset type 1 diabetes. Patient's fibroblasts and COS-7 cells transfected with wildtype or mutant VDRs were studied for ligand-binding capacity, transactivation activity using two gene promoters [CYP-24, a classical 1,25(OH)2D3-responsive gene, and relB, a critical NF-κB component for regulation of dendritic cell differentiation], VDR-RXR heterodimers association to CYP 24 VDREs by gel mobility shift assays, and co-activator binding by Glutathione-S-transferase pull-down assays. Results: Two novel compound heterozygous mutations (L263R and R391S) were identified in the VDR ligand-binding domain in this child. Both mutations significantly impaired VDR ligand-binding capacity but had dissociated effects on CYP-24 and RelB promoter responses to vitamin D. CYP 24 response binding to SRC-1 and RXR-heterodimer binding to CYP24 VDREs were abolished in L263R mutants but normal or partially altered in R391S mutants. In the opposite, RelB responses to vitamin D were close to normal in L263R mutants but abolished in R391S mutants. Conclusions: We report the first clinical association between HVDRR, total alopecia, and early childhood–onset type 1 diabetes. Mutations in the VDR ligand-binding domain may hamper the 1,25(OH)2D3–mediated relB responses, an effect that depends on the site of the VDR mutation and cannot be anticipated from VDR ligand-binding ability or CYP-24 response. Based on these results, we propose to survey the immune function in patients with HVDRR, including those with moderate features of rickets.